Calliditas Interim Report January to June 2024 – Optimum Strategic Communications

Key takeaways from Q2, 2024

In April, Calliditas read out positive data from the Nefecon Open Label Phase 3 Extension trial.
In May, Calliditas read out positive topline results from the setanaxib Phase 2 trial in head and neck cancer.
In May, Calliditas’ partner Everest Medicines announced the commercial launch of Nefecon in China.
In May, Calliditas’ partner STADA received a positive CHMP opinion recommending full approval for Kinpeygo^® in EU for the treatment of IgA nephropathy.
In June, Calliditas announced the issuance by the United States Patent and Trademark Office (USPTO) of a new patent for setanaxib for treatment of cancer. The patent will have an expiration date in 2039.